To access this element change to forms mode OFF
Grant Award View - GA30002
Oncogenic signalling crosstalk between MYD88 and CD79B mutations
GA ID:
GA30002
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
25-Oct-2018
Publish Date:
21-Dec-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2021
Value (AUD):
$848,386.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
Oncogenic signalling crosstalk between MYD88 and CD79B mutations
Purpose:
Lymphoma is a blood cancer of lymphocytes, which results from uncontrolled growth and survival. The advent of DNA sequencing revealed that many lymphomas carry concurrent mutations in two signalling molecules, MYD88 and CD79B. The project will investigate how these mutant proteins cooperatively dysregulate signalling to understand the pathogenesis of this disease. It will also reinforce the rationale to use front-line drugs and identify new therapeutic targets.
GO ID:
GO Title:
NHMRC Project Grant Scheme
Internal Reference ID:
GNT1159749
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Australian National University
Recipient ABN:
52 234 063 906
Grant Recipient Location
Suburb:
Canberra City
Town/City:
Canberra City
Postcode:
2601
State/Territory:
ACT
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT
Postcode:
Country:
AUSTRALIA